论文部分内容阅读
近年来发现,一些药物如无环鸟嘌呤(acyclovir)、溴乙烯脱氧尿苷(bro-movinyl deoxyuridine)等虽对单纯疱疹病毒有抑制作用,但对宿主细胞也伴随轻中度的毒性,且长期应用可产生耐药性。然而,在寻找优良的抗病毒药物的过程中,我们发现阿托品不仅对单纯疱疹病毒血清I型(HSV-1)有抑制作用,且对其它胞膜病毒如流感病毒等也具有对抗作用。 理论根据 Balbino A等报告,阿托品200μg/ml浓度可阻断新感染的HSV-1病毒颗粒产生,其抗病毒机制可能是抑制病毒蛋白的糖基化作用。文献指出,阿托品作为局部抗病毒药可以试用,但尚不能用于全身性病毒感染,这是由于该药的抗胆硷作用限制阿托品的用量。因为Ya-mazaki Z和Tagaya I报告,阿托品的抗病毒作用随用药剂量增大而增强,有显著的剂量依赖性关系。
In recent years, it has been found that some drugs such as acyclovir and bro-movinyl deoxyuridine inhibit the herpes simplex virus but are also accompanied with mild to moderate toxicity to host cells, and long-term Application can produce drug resistance. However, in the search for good antiviral drugs, we found that atropine not only inhibits herpes simplex virus serotype I (HSV-1), but also antagonizes other membrane viruses such as influenza virus. Theory According to Balbino A et al reported that atropine 200μg / ml concentration can block the newly infected HSV-1 virus particles, the anti-viral mechanism may be inhibition of viral protein glycosylation. The literature suggests that atropine can be used as a topical antiviral but can not yet be used for systemic viral infections due to its anticholinergic effect that limits the amount of atropine used. Because Ya-mazaki Z and Tagaya I reported that the antiviral effect of atropine increased with the dose increased, in a significant dose-dependent relationship.